SCHEMBL30445759

SCHEMBL30445759

COc1ccc(-c2nc3ccccc3o2)cc1NC(=O)c1ccc(O[C@H](C)c2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.74
▸ TP53 P04637 8/20 0.64
▸ ALDH1A1 P00352 2/20 0.60
▸ NPSR1 Q6W5P4 2/20 0.60
▸ HSD17B10 Q99714 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ POLB P06746 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ LMNA P02545 3/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ USP2 O75604 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ PTGS2 P35354 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25239230 1.00 MAPT (0.74) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL25239232 1.00 MAPT (0.74) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL25217880 0.85 TP53 (0.75) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL25209983 0.83 MAPT (0.78) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL30445554 0.83 MAPT (0.78) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL16384037 0.78 TP53 (1.00) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL30445802 0.77 MAPT (0.66) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL25232353 0.77 MAPT (0.66) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL30445856 0.75 MAPT (0.62) MAPTTP53ALDH1A1NPSR1HSD17B10
SCHEMBL25257561 0.75 MAPT (0.62) MAPTTP53ALDH1A1NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172913-A1 COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172913-A1 COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS TARBP1, NFATC1, TARDBP MAPT 781/4885TP53 821/4885ALDH1A1 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback